| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 01/27/2005 | WO2005007845A2 Transgenic cells |
| 01/27/2005 | WO2005007841A1 Variant serine acetyltransferase and process for producing l-cysteine |
| 01/27/2005 | WO2005007832A2 System for external control of oncolytic virus replication |
| 01/27/2005 | WO2005007829A2 Materials and methods for the modulation of cyclin-dependent kinase inhibitor-like polypeptides in maize |
| 01/27/2005 | WO2005007827A2 Avian adeno-associated virus vector |
| 01/27/2005 | WO2005007826A2 Production of aromatic carotenoids in gram negative bacteria |
| 01/27/2005 | WO2005007825A2 Modulation of aminopeptidase n expression |
| 01/27/2005 | WO2005007823A2 Compositions, kits, and methods for stimulation of homologous recombination |
| 01/27/2005 | WO2005007822A2 Method for assaying protein-protein interaction |
| 01/27/2005 | WO2005007818A2 Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof |
| 01/27/2005 | WO2005007814A2 Genome mapping of functional dna elements and cellular proteins |
| 01/27/2005 | WO2005007808A2 Hiv polynucleotides and polypeptides derived from botswana mj4 |
| 01/27/2005 | WO2005007805A2 ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 01/27/2005 | WO2005007803A2 Selection free growth of host cells containing multiple integrating vectors |
| 01/27/2005 | WO2005007800A2 Monoclonal antibody against platelet membrane glycoprotein vi |
| 01/27/2005 | WO2005007700A1 Antibodies to cd44 vra and methods of use |
| 01/27/2005 | WO2005007699A2 Human antibody molecules for il-13 |
| 01/27/2005 | WO2005007693A1 Design and use of kazal-type |
| 01/27/2005 | WO2005007691A2 East coast fever vaccine based on ctl-specific schizont antigens |
| 01/27/2005 | WO2005007689A1 Alphavirus-based cytomegalovirus vaccines |
| 01/27/2005 | WO2005007687A1 Compositions and methods for modulating ovarian follicular initiation |
| 01/27/2005 | WO2005007679A1 Membrane protein library for proteome analysis and method for preparing same |
| 01/27/2005 | WO2005007623A2 Inhibition of syk kinase expression |
| 01/27/2005 | WO2005007199A1 COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
| 01/27/2005 | WO2005007196A2 Lipid encapsulated interfering rna |
| 01/27/2005 | WO2005007189A1 Subunit vaccine against respiratory syncytial virus infection |
| 01/27/2005 | WO2005007109A2 Methods and compositions for cancer therapy using a novel adenovirus |
| 01/27/2005 | WO2005007098A2 Nucleic acid therapy to enhance cartilage repair |
| 01/27/2005 | WO2005007072A2 Methods and pharmaceutical compositions for healing wounds |
| 01/27/2005 | WO2005006958A2 Modulation of ceacam1 expression |
| 01/27/2005 | WO2005006864A1 Genetic vaccines for cancer therapy |
| 01/27/2005 | WO2005006847A1 Method of constructing plant showing improved growtn under regulation of nitrogen |
| 01/27/2005 | WO2005006846A2 Generation of plants with altered oil content |
| 01/27/2005 | WO2005006845A2 Generation of plants with altered oil content |
| 01/27/2005 | WO2004101822A3 Use of bage (b melanoma antigens) loci as tumour markers |
| 01/27/2005 | WO2004096846A3 Nogo-b, a regulator of endothelial cell function and vessel remodeling |
| 01/27/2005 | WO2004087046A3 TREATMENT OR PREVENTION OF cGMP-DEPENDENT PATHOPHYSIOLOGY WITH A MUTANT VARIANT OF SOLUBLE GUANYLYL CYCLASE |
| 01/27/2005 | WO2004082517A3 Animal exhibiting ptsd-like behavior, per pct rule 4.3 |
| 01/27/2005 | WO2004081534A3 Phosphokinase assay |
| 01/27/2005 | WO2004081026A3 Polypeptides |
| 01/27/2005 | WO2004074514A3 Method of diagnosis of type 2 diabetes and early onset thereof |
| 01/27/2005 | WO2004074499A3 Combinatorial dna library for producing modified n-glycans in lower eukaryotes |
| 01/27/2005 | WO2004074325A3 Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| 01/27/2005 | WO2004067707A3 Administration of transposon-based vectors to reproductive organs |
| 01/27/2005 | WO2004063359A3 Method for producing carotenoids or their precursors using genetically modified organisms of the blakeslea genus, carotenoids or their precursors produced by said method and use thereof |
| 01/27/2005 | WO2004060053A3 Transgenic mice expressing human cd20 |
| 01/27/2005 | WO2004053090A3 Method and system for utilizing somatic cell nuclear transfer embryos as cell donors for additional nuclear transfer |
| 01/27/2005 | WO2004052300A3 Modulation of alpha-methylacyl-coa racemase expression |
| 01/27/2005 | WO2004031730A3 High sensitivity quantitation of peptides by mass spectrometry |
| 01/27/2005 | WO2004028447A3 Novel compositions and methods for the treatment of psoriasis |
| 01/27/2005 | WO2004027035A3 Riboswitches, methods for their use, and compositions for use with riboswitches. |
| 01/27/2005 | WO2004024756A3 Orthopoxvirus antigens and use thereof |
| 01/27/2005 | WO2003100072A3 Method for the production of sulphur-containing fine chemicals by fermentation |
| 01/27/2005 | WO2003091412A3 Generation of plants with improved pathogen resistance |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003087334A3 Use of aav integration efficiency element for mediating site-specific integration of a transcription unit |
| 01/27/2005 | WO2003080807A3 Compositions and methods for suppressing eukaryotic gene expression |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2003072600A3 Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53 |
| 01/27/2005 | WO2003062400A3 Fiber shaft modifications for efficient targeting |
| 01/27/2005 | WO2003057826A3 SOLUBLE GLcNAC PHOSPHOTRANSFERASE |
| 01/27/2005 | WO2003054211A3 Receptors for hypersensitive response elicitors and uses thereof |
| 01/27/2005 | WO2002042417A3 Human erg2 potassium channel |
| 01/27/2005 | US20050022272 Selfing, backcrosses, hybrid production, and crosses to populations to produce hybrid seeds and plants with superior characteristics, such as herbicide resistance, insect resistance, modified fatty acid metabolism, modified carbohydrate metabolism, and resistance to bacterial, fungal or viral disease |
| 01/27/2005 | US20050022270 Expression vector comprising nucleotide sequences coding delta epoxygenase for use in transforming and enhancing fatty acid concentration in plants |
| 01/27/2005 | US20050022269 Expression vector comprising nucleotide sequences coding cartenoid biosynthetic polypeptides for use enhancing cartenoid biosynthesis in darkness |
| 01/27/2005 | US20050022267 Methods for Agrobacterium-mediated transformation of dandelion |
| 01/27/2005 | US20050022266 Using expression vector comprising Hap3 transcription factor polynucleotides and herbicide and drought resistant genes to transform and generate stress resistant corn |
| 01/27/2005 | US20050022265 Enhancing breadmaking quality of flour via increasing expression of puroindoline-b protein in plants; transgenic plants and food processing |
| 01/27/2005 | US20050022263 DNA and vector for repressing expression of gene of lachrymatory factor-producing enzyme, method for repressing expression of gene of lachrymatory factor-producing enzyme with them and vegetables having repressed expression of gene of lachrymatory factor-producing enzyme |
| 01/27/2005 | US20050022262 Control of post-transcriptional gene silencing in plants |
| 01/27/2005 | US20050022261 Glyphosate resistant plants using hybrid promoter constructs |
| 01/27/2005 | US20050022260 Genetically engineered avian for use as bioreactors in heterologous protein expression; animal model for disease |
| 01/27/2005 | US20050022259 Genetically engineered embryonic stem cells for use in prevention and treatment of cell proliferfative disorders; gene therapy |
| 01/27/2005 | US20050022257 Transgenic animals harboring appallele having swedish mutation |
| 01/27/2005 | US20050022256 Triple transgenic mouse model of alzheimer's disease |
| 01/27/2005 | US20050020817 Nucleotide sequences coding tumor marker protein for use as tools in detection, prevention a nd treatment of cell proliferative disorders |
| 01/27/2005 | US20050020813 Streptococcus pneumoniae proteins and nucleic acids |
| 01/27/2005 | US20050020530 Treatment of parkinson's disease with oligonucleotides |
| 01/27/2005 | US20050020529 Delivery construct for antisense nucleic acids and methods of use |
| 01/27/2005 | US20050020527 Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders |
| 01/27/2005 | US20050020526 Oligodeoxynucleotide intervention for prevention and treatment of sepsis |
| 01/27/2005 | US20050020525 first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide |
| 01/27/2005 | US20050020523 Modified antisense nucleotides complementary to a section of the human haras gene |
| 01/27/2005 | US20050020522 Induce mitrosis and smooth muscle proliferation; administering to cell or tissue a polynucleotide which codes endothelial growth factor |
| 01/27/2005 | US20050020521 In vivo gene silencing by chemically modified and stable siRNA |
| 01/27/2005 | US20050020520 DNA vaccine containing tumor-associated gene and cytokine gene and method of preparation the same |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020494 Modified human growth hormone |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |
| 01/27/2005 | US20050019931 Nucleic acids encoding antifungal drug targets and methods of use |
| 01/27/2005 | US20050019930 Generating transplastomic plant comprising gene which confer herbicide resistance; biological pest control |
| 01/27/2005 | US20050019929 Deleted adenovirus vectors and methods of making and administering the same |
| 01/27/2005 | US20050019928 Modified adenoviral vector for use as gene transfer and replication tool in genetic engineering |
| 01/27/2005 | US20050019927 DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019925 Transforming cells with vector comprising dihydrofolate reductase marker for use as tool in transfer of heterologous nucleotide sequences |
| 01/27/2005 | US20050019924 Modified yeast artificial chromosome for transfer of heterologous nucleotide sequences into eukaryotic cells and preparation of disease and herbicide resistant plants; alcoholic beverages |
| 01/27/2005 | US20050019922 Site-specific cell perforation technique |